

REMARKSTHE AMENDMENTS

Applicants have amended claims 1 and 2 to delete the phrase -- the group consisting of -- and to delete the phrase -- and VX-944 -- after the term "an IMPDH inhibitor selected from" to further clarify the scope of the IMPDH inhibitors intended.

Applicants have amended claim 4 by deleting the phrase -- or VX-944 -- to further clarify the scope of the IMPDH inhibitors intended in the composition.

None of the above amendments add any new matter. These amendments are further discussed below in the context of the Examiners rejections.

THE REJECTIONSIII. 35 U.S.C. § 112, First Paragraph

Claims 1-7 are rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. Specifically, the Examiner asserts that the specification does not reasonably provide enablement for compositions and methods using VX-944 because the structure has not been published and the compound is not commercially available.

As noted above, applicants have amended claims 1-2 and 4 to delete reference to VX-944 thereby clarifying the scope of the IMPDH inhibitor intended. Applicant's claims as amended would allow the skilled practitioner to practice the invention commensurate in scope with the claims. Thus, applicants have obviated the Examiner's rejection of claims 1-2, and 4. Additionally, claim 3 is now sufficiently

enabled in light of applicants amendments clarifying the scope of the compositions and methods intended in claims 1-2 and 4.

Furthermore, because claims 5-7 depend either directly or indirectly from claims 2-4, they, too, are in condition for allowance. Consequently, applicants request that the Examiner withdraw this 35 U.S.C. § 112 first paragraph rejection of claims 1-7.

For the reasons set forth above, applicants request that the Examiner withdraw these 35 U.S.C. § 112, first paragraph rejections.

CONCLUSION

Applicants request that the Examiner enter the above amendments, consider the accompanying remarks, and allow the pending claims to pass to issue.

Respectfully submitted,



Michael C. Badia  
Reg. No. 51,424  
Agent for Applicants  
Nandakumar Govindaswamy  
Ltd. Recognition  
Attorney for Applicants

Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, MA 02139-4242  
Tel.: (617)444-6467  
Fax.: (617)444-6483